2025
Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Nousias O, Mandell J, Anderson K, Townsend J. Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC. Lung Cancer 2025, 202: 108487. PMID: 40090261, DOI: 10.1016/j.lungcan.2025.108487.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsCell lung cancerLung cancer patientsEvolution of drug resistanceLung cancerDrug resistanceCancer patientsTyrosine kinase inhibitor therapyKinase inhibitor therapyTyrosine kinase inhibitorsPersonalized therapeutic strategiesTKI therapyInhibitor therapyTherapeutic failureResistance mutationsTherapeutic efficacyKinase inhibitorsAPOBEC mutationsTherapeutic strategiesTreatment efficacyCancer progressionImprove outcomesCancerCardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis
Hammer M, Tysarowski M, Fuss C, Bader A. Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis. Echocardiography 2025, 42: e70131. PMID: 40067334, DOI: 10.1111/echo.70131.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCardiac magnetic resonance imagingMagnetic resonance imagingAssociated with immune-related adverse eventsCardiac immune-related adverse eventsMechanisms of immune checkpoint inhibitorsICI-associated myocarditisICI-related myocarditisResonance imagingPersonalized cancer immunotherapySevere cardiovascular complicationsImmune tolerance pathwayCheckpoint inhibitorsCancer immunotherapyCardiac complicationsCombination therapyTumor cytotoxicityClinical presentationCardiovascular complicationsAdverse eventsTherapeutic efficacyOncological treatmentTherapeutic strategiesMyocarditisCardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee.
Esteso P, Auerbach S, Bansal N, Harris R, Soslow J, Birnbaum B, Conway J, Cripe L, Nandi D, Hayes E, Gambetta K, Hall E, Hsu D, Kaufman B, Rosenthal D, Kirmani S, Ploutz M, Lal A, Peng D, Villa C, Shugh S, Wittlieb-Weber C, Shih R. Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. Cardiology In The Young 2025, 1-6. PMID: 40012319, DOI: 10.1017/s1047951125000587.Peer-Reviewed Original ResearchDuchenne muscular dystrophyCardiac medicationsMuscular dystrophyCardiac careAdvanced Cardiac Therapies Improving Outcomes NetworkManagement of Duchenne muscular dystrophyImprove cardiac outcomesLoss of dystrophinAmerican College of CardiologyOptimal therapeutic efficacyExpert opinion statementsAmerican Heart AssociationCardiac outcomesImprove cardiac prognosisCardiomyopathy progressionTherapeutic efficacyCardiac prognosisHeart AssociationDisease progressionCardiac treatmentConsensus recommendationsOutcomes NetworkAmerican CollegeDystrophyCardiomyopathySORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer
Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich T, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim S, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers 2025, 17: 244. PMID: 39858026, PMCID: PMC11763764, DOI: 10.3390/cancers17020244.Peer-Reviewed Original ResearchEpidermal growth factor receptorOvarian cancerRecurrent tumorsSortilin-related receptor 1Therapeutic efficacy of carboplatinResistant to conventional chemotherapyResistant ovarian cancerMolecular mechanisms of chemoresistanceCancer models in vitroEfficacy of carboplatinRecurrent ovarian cancerOvarian cancer treatmentEffective targeted therapiesMechanisms of chemoresistancePro-tumor functionsGrowth factor receptorXenograft mouse modelConventional chemotherapyStabilization of epidermal growth factor receptorModel in vitroPro-tumorEnhanced chemoresistanceCarboplatin resistanceTherapeutic efficacyFactor receptor
2024
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou L, Sarrafpour S, Teng C, Liu J. Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions. The Yale Journal Of Biology And Medicine 2024, 97: 491-503. PMID: 39703610, PMCID: PMC11650918, DOI: 10.59249/hwid7537.Peer-Reviewed Original ResearchConceptsAdeno-associated virusOcular gene therapyGene therapyFood and Drug AdministrationViral vectorsImmune responsePotential application of gene therapyClinical trialsApproval of voretigene neparvovecViral vector-based therapyApplication of gene therapyImproved delivery techniquesVector-based therapyImmune-privileged statusInduce immune responsesReduced immune responseVoretigene neparvovecContralateral eyeRetinal dystrophyImmune privilegeOcular diseasesDeliver genesEye diseaseTherapeutic efficacyTherapyComparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups
Olkowski C, Basuli F, Fernandes B, Ghaemi B, Shi J, Zhang H, Farber J, Escorcia F, Choyke P, Jacobson O. Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups. Molecular Pharmaceutics 2024, 22: 533-543. PMID: 39680709, DOI: 10.1021/acs.molpharmaceut.4c01101.Peer-Reviewed Original ResearchHuman HDAC6 senses valine abundancy to regulate DNA damage
Jin J, Meng T, Yu Y, Wu S, Jiao C, Song S, Li Y, Zhang Y, Zhao Y, Li X, Wang Z, Liu Y, Huang R, Qin J, Chen Y, Cao H, Tan X, Ge X, Jiang C, Xue J, Yuan J, Wu D, Wu W, Jiang C, Wang P. Human HDAC6 senses valine abundancy to regulate DNA damage. Nature 2024, 637: 215-223. PMID: 39567688, DOI: 10.1038/s41586-024-08248-5.Peer-Reviewed Original ResearchConceptsHuman histone deacetylase 6Active DNA demethylationDNA demethylationValine deprivationDNA damageTen-eleven translocationRegulating DNA damageHistone deacetylase 6Repeat domainTherapeutic efficacy of PARP inhibitorsBind valineEfficacy of PARP inhibitorsCellular functionsPatient-derived xenograft modelsCytoplasmic shuttlingInduce DNA damageBranched amino acidsProtein synthesisAmino acidsIntracellular levelsPARP inhibitorsDNALevels of valineTumor growthTherapeutic efficacyDeciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies
Weitzen M, Shahbazy M, Kapoor S, Caron E. Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies. Frontiers In Immunology 2024, 15: 1442783. PMID: 39301027, PMCID: PMC11410602, DOI: 10.3389/fimmu.2024.1442783.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMass spectrometryHLA-EHLA moleculesT-cell-directed immunotherapyCD8+ T cellsNovel cell surface antigensNon-classical HLA-EHLA-E moleculesCell surface antigensPeptides to CD8T cellsMRNA vaccinesTherapeutic efficacySurface antigensImmunotherapyMoleculesSpectrometryTherapeutic targetImmunopeptidomePathogen-derivedCD8Peptide repertoirePeptide fragmentsHLAMinimal polymorphismW161 Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications
Lanier R, Bogenschutz M, Schindler E, Kelmendi B, Durgin C, Ashworth J. W161 Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications. Drug And Alcohol Dependence 2024, 260: 110862. DOI: 10.1016/j.drugalcdep.2023.110862.Peer-Reviewed Original ResearchEfficacy of psilocybinTherapeutic efficacyIs Lipid Metabolism of Value in Cancer Research and Treatment? Part I- Lipid Metabolism in Cancer
Nassar A, Nie X, Zhang T, Yeung J, Norris P, He J, Ogura H, Babar M, Muldoon A, Libreros S, Chen L. Is Lipid Metabolism of Value in Cancer Research and Treatment? Part I- Lipid Metabolism in Cancer. Metabolites 2024, 14: 312. PMID: 38921447, PMCID: PMC11205345, DOI: 10.3390/metabo14060312.Peer-Reviewed Original ResearchMass spectrometryLipid metabolismTherapeutic efficacy of treatmentLipidomic studiesEfficacy of treatmentStudy of lipidsEmergence of lipidomicsLipid categoriesSpectrometryEnergy storageTumor microenvironmentPharmaceutical candidatesTherapeutic efficacyLipidomicsCancer patientsLipid profileCancer samplesCancerLarge-scale studiesCancer researchTargeted approachAlterationsDisease developmentCell growthMetabolismNetwork-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis
Rosenberger G, Li W, Turunen M, He J, Subramaniam P, Pampou S, Griffin A, Karan C, Kerwin P, Murray D, Honig B, Liu Y, Califano A. Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis. Nature Communications 2024, 15: 3909. PMID: 38724493, PMCID: PMC11082183, DOI: 10.1038/s41467-024-47957-3.Peer-Reviewed Original ResearchConceptsMechanism of cell responseResistance mechanismsSignaling pathway responsesDrug resistance mechanismsEnzyme/substrate interactionsAdaptive resistance mechanismsNetwork rewiringPhosphorylation stateSignaling pathway activationDrug perturbationsProteomic technologiesSignaling crosstalkPathway responsesInhibitor designPathway activationCancer drug resistance mechanismsCell adaptive responsesAdaptive responsePhosphatase activityNetwork-based methodologyRewiringTherapeutic efficacyPhosphoproteome coverageCell responsesControl mediumPilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation
Grun M, Honhar P, Wang Y, Rossano S, Khang M, Suh H, Fowles K, Kliman H, Cavaliere A, Carson R, Marquez‐Nostra B, Saltzman W. Pilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation. Bioengineering & Translational Medicine 2024, 9: e10661. PMID: 39553429, PMCID: PMC11561825, DOI: 10.1002/btm2.10661.Peer-Reviewed Original ResearchVaginal dosage formsBioadhesive nanoparticlesCynomolgus monkeysAnalysis of inflammatory biomarkersVaginal microbicidesVaginal canalMultiple dosesInflammatory biomarkersTherapeutic efficacyVaginal fluidSystemic circulationLong-term deliveryNoninvasive imagingClinical translationDosage formsNon-human primatesDelivery vehiclesMonkeysDeliveryVaginitisUterusMicrobicidesSafety evaluationBiodistributionDoseGonadal hormone deprivation regulates response to tibolone in neurodegenerative pathways
McGovern A, Arevalo M, Ciordia S, Garcia-Segura L, Barreto G. Gonadal hormone deprivation regulates response to tibolone in neurodegenerative pathways. The Journal Of Steroid Biochemistry And Molecular Biology 2024, 241: 106520. PMID: 38614433, DOI: 10.1016/j.jsbmb.2024.106520.Peer-Reviewed Original ResearchHormone therapyEfficacy of hormone therapyEffects of hormone therapyPathways of neurodegenerationBilateral oophorectomyHormone deprivationAndrogen pathwayIncreased risk of neurodegenerationTherapeutic efficacyTiboloneOxidative phosphorylationIncreased riskProteomic analysisCalcium signalingCellular respirationHormonal declineNeurodegenerative pathwaysDrug typeRisk of neurodegenerationInterconnected pathwaysPathwayNeurodegenerationSexPsilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Schindler E, Sewell R, Gottschalk C, Flynn L, Zhu Y, Pittman B, Cozzi N, D'Souza D. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal Of The Neurological Sciences 2024, 460: 122993. PMID: 38581739, DOI: 10.1016/j.jns.2024.122993.Peer-Reviewed Original ResearchConceptsAttack frequencyCluster headacheCluster headache attack frequencyExtension phaseEffects of repeated treatmentReduction of attack frequencyPlacebo-controlled studyHeadache attack frequencyAdministration of psilocybinRandomized controlled trialsDouble-blindPsilocybin administrationPulse regimenAdverse eventsPulse regimensHeadache diaryTherapeutic efficacyDrug sessionsPulse administrationHeadacheStudy participantsWeeksEstablished and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani Y, Jansen C, Gerke M, Bilen M. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma. Immunotherapy 2024, 16: 405-426. PMID: 38264827, PMCID: PMC11913054, DOI: 10.2217/imt-2023-0267.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaImmune checkpoint inhibitorsBiomarker of immunotherapyRisk of adverse eventsSignificant side effectsCheckpoint inhibitorsDevelopment of biomarkersAdverse eventsImmunotherapyTherapeutic efficacySide effectsPatientsClinical biomarkersPatient's diseaseTherapeutic biomarkersClinician's abilityBiomarkersCarcinomaPatient careImproving clinicians' abilityEfficacyTargeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
Alcantara M, Tang W, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal S, Kortylewski M. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. Frontiers In Immunology 2024, 14: 1274781. PMID: 38259453, PMCID: PMC10800835, DOI: 10.3389/fimmu.2023.1274781.Peer-Reviewed Original ResearchImmune checkpoint blockadeDendritic cellsCancer patientsBladder cancerT cellsTumor-associated antigen-presenting cellsTherapeutic efficacyLesser extent IL-10T cell-based immunotherapyImmune checkpoint inhibitorsTumor immune evasionAntitumor immune responseCD8 T cellsRegulatory T cellsBladder cancer immunotherapyCell-based immunotherapyAntigen-presenting cellsSTAT3 activationRenal cancer patientsBladder cancer patientsImmune cell activityMyeloid immune cellsICB resistanceIpilimumab immunotherapyCheckpoint inhibitors
2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Bergaggio E, Tai W, Aroldi A, Mecca C, Landoni E, Nüesch M, Mota I, Metovic J, Molinaro L, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco R, Li T, Klein D, Irvine D, Papotti M, Savoldo B, Dotti G, Chiarle R. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 2023, 41: 2100-2116.e10. PMID: 38039964, PMCID: PMC10793157, DOI: 10.1016/j.ccell.2023.11.004.Peer-Reviewed Original ResearchConceptsALK inhibitorsALK expressionChimeric antigen receptor TBest tumor antigensPromising clinical activityExpression of ALKMost normal tissuesHematologic malignanciesClinical activityMost neuroblastomasAnaplastic lymphoma kinase (ALK) receptorTherapeutic successTumor antigensPotent efficacySolid tumorsTherapeutic efficacyNeuroblastomaTumor growthOncogenic driversNeuroblastoma cellsNormal tissuesALKKinase receptorsMonotherapyInhibitorsDelivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance
Chen L, Zhao R, Kang Z, Cao Z, Liu N, Shen J, Wang C, Pan F, Zhou X, Liu Z, Yang Y, Chen Q. Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance. Journal Of Controlled Release 2023, 363: 43-56. PMID: 37734673, DOI: 10.1016/j.jconrel.2023.09.028.Peer-Reviewed Original ResearchConceptsShort-chain fatty acid butyrateF. nucleatumFatty acid butyrateColorectal tumorsColorectal cancerInvasion of F. nucleatumTherapeutic efficacy of oxaliplatinEfficacy of oxaliplatinProgression of colorectal cancerEffect of butyrateOrthotopic colorectal tumorsFusobacterium nucleatumClinical application prospectsTherapeutic efficacyDrug resistanceIntravenous administrationColorectal cancer tissuesIntravenous injectionOral administrationCancer resistanceOral deliveryTumorKilling effectCancer tissuesChemoresistanceReview of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome
Walters A, Li Y, Koo B, Ondo W, Weinstock L, Champion D, Afrin L, Karroum E, Bagai K, Spruyt K. Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome. Brain 2023, 147: 26-38. PMID: 37633259, PMCID: PMC10796165, DOI: 10.1093/brain/awad283.Peer-Reviewed Original ResearchConceptsRestless legs syndromeMu-opioid receptorsRLS patientsEndogenous opioidsLegs syndromeOpioid receptorsSerum ironΒ-endorphinMelanocortin systemIdiopathic restless legs syndromeRLS-like symptomsPeriodic limb movementsLow serum ironWild-type miceSensory changesMelanocyte stimulating hormoneReceptor blockersSerum ferritinAutopsy studyStriatal dopamineAdrenocorticotropic hormoneStimulating hormoneDopaminergic systemMouse modelTherapeutic efficacyTherapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury
Terada K, Sasaki M, Nagahama H, Kataoka-Sasaki Y, Oka S, Ukai R, Yokoyama T, Iizuka Y, Sakai T, Fukumura S, Tsugawa T, Kocsis J, Honmou O. Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury. Pediatric Research 2023, 94: 1921-1928. PMID: 37422495, DOI: 10.1038/s41390-023-02717-9.Peer-Reviewed Original ResearchConceptsPerinatal brain injuryBrain injuryMesenchymal stem cellsIntravenous infusionVehicle groupBrain volumeTherapeutic efficacyInfused mesenchymal stem cellsLeft common carotid arteryHistological analysisNon-ischemic hemispherePostnatal day 7Common carotid arteryEmbryonic day 18Stem cellsHypoxia-ischemiaMSC infusionPreterm infantsGABAergic cellsNeurological functionSignificant complicationsCortical synapsesFunctional improvementCarotid arteryIntravenous administration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply